# UNIFIED STYLE GUIDE: AER-HTA HYBRID APPROACH
## For Lowe Syndrome Gene Therapy HTA Report

**Version:** 1.0
**Date:** November 11, 2025
**Purpose:** Establish consistent writing style combining American Economic Review (AER) academic rigor with Health Technology Assessment (HTA) practical comprehensiveness

---

## I. EXECUTIVE PHILOSOPHY

This guide synthesizes two distinct writing traditions:

1. **AER Academic Style:** Analytical, concise, methodologically rigorous economic writing suitable for peer-reviewed publication
2. **HTA Report Style:** Comprehensive, accessible, implementation-focused writing for healthcare decision-makers

**Our Hybrid Approach:**
- Adopt AER formatting conventions (tables, equations, citations) for academic credibility
- Retain HTA comprehensiveness and practical detail for decision-making utility
- Balance analytical tone with accessibility
- Maintain methodological rigor while addressing real-world implementation

---

## II. DOCUMENT STRUCTURE

### A. Overall Organization

**Use Modified Roman Numeral System with Descriptive Titles:**

```
I. Disease Background and Unmet Medical Need
   A. Lowe Syndrome Overview
      1. Disease definition and nomenclature
      2. Genetic basis and molecular pathophysiology
   B. Clinical Presentation by Organ System
      1. Ocular manifestations
      2. Neurological manifestations
      3. Renal manifestations

II. Epidemiological Framework and Target Population
   A. Prevalence Estimation Methodology
   B. Geographic Distribution
```

**Rationale:**
- Roman numerals (AER convention) provide academic structure
- Descriptive section titles (HTA convention) improve navigation and accessibility
- Numbered subsections maintain hierarchy without excessive formality

### B. Front Matter

**Include:**
1. **Title:** Clear, descriptive (not just "Report")
2. **Abstract:** 100-150 words (AER: 100 words max; we extend slightly for HTA context)
3. **Executive Summary:** 2-3 pages (HTA convention, not in pure AER)
   - Key findings in bullet format
   - Clear recommendation summary
   - Accessibility for non-technical readers

**Format:**
```
Cost-Effectiveness of Gene Therapy for Lowe Syndrome:
An Economic Evaluation for Health Technology Assessment

Abstract: [100-150 words summarizing objective, methods, results, conclusion]

Executive Summary

Key Findings
- Finding 1
- Finding 2
- Finding 3

[Body begins with I. Disease Background... NO separate "Introduction" heading]
```

### C. Section Order

**Recommended Structure:**

1. **Abstract** (100-150 words)
2. **Executive Summary** (2-3 pages, HTA convention)
3. **I. Disease Background and Unmet Medical Need** (replaces traditional "Introduction")
4. **II. Epidemiological Framework and Target Population**
5. **III. Methodology**
   - A. Model Structure
   - B. Clinical Parameters
   - C. Cost Parameters
   - D. Utility Parameters
   - E. Model Implementation
6. **IV. Results**
   - A. Base Case Cost-Effectiveness
   - B. Sensitivity Analysis
   - C. Scenario Analysis
7. **V. Broader Value Considerations** (HTA extension beyond traditional AER)
8. **VI. Strategic Landscape and Implementation** (HTA convention)
9. **VII. Evidence Development Plan** (HTA convention)
10. **VIII. Discussion and Conclusions**
11. **References**
12. **Appendices** (technical details, supplementary tables)

---

## III. WRITING TONE AND STYLE

### A. General Principles

**1. Analytical Clarity (AER)**
- Present evidence objectively
- Explain economic trade-offs analytically
- Cite literature to support claims
- Avoid marketing language or advocacy

**Good Example:**
> "The incremental cost-effectiveness ratio of 328,288 dollars per QALY exceeds conventional thresholds of 100,000 to 150,000 dollars per QALY but falls within ranges considered for ultra-rare diseases under NICE's Highly Specialised Technologies framework (up to 300,000 pounds per QALY, approximately 380,000 dollars)."

**Avoid:**
> "This groundbreaking therapy offers amazing value and should definitely be adopted by all healthcare systems."

**2. Accessible Precision (HTA)**
- Define technical terms on first use
- Use clear subsection headings
- Include bullet points for complex information
- Explain clinical and economic concepts for multidisciplinary audience

**Good Example:**
> "Lowe syndrome is caused by mutations in the *OCRL* gene, which encodes a phosphatidylinositol 4,5-bisphosphate 5-phosphatase enzyme. This enzyme deficiency leads to three primary manifestations:
> - Congenital cataracts (100% of patients)
> - Intellectual disability (90% of patients)
> - Progressive kidney failure (100% of patients)"

**3. Conciseness with Completeness**
- AER principle: Eliminate unnecessary words
- HTA adaptation: Retain essential detail for decision-making
- Move highly technical content to appendices
- Main text should be self-contained but not exhaustive

**Apply These Rules:**
- "in order to" â†’ "to"
- "whether or not" â†’ "whether"
- "is equal to" â†’ "equals"
- BUT: Do not sacrifice clarity for brevity in HTA sections (e.g., eligibility criteria, monitoring requirements)

### B. Voice and Perspective

**Use First Person Plural (Standard in Both Styles):**
- "We evaluate..."
- "Our analysis demonstrates..."
- "We estimate..."
- "The model predicts..."

**Avoid:**
- Passive voice when active is clearer
- "It is shown that..." â†’ "We show that..."
- "It can be seen..." â†’ "Table 1 shows..."

### C. Language Conventions

**Economics/HTA Terminology:**

**Appropriate:**
- "We estimate the incremental cost-effectiveness ratio..."
- "Results suggest gene therapy may be cost-effective under optimistic scenarios"
- "The model predicts ESKD onset at age 28..."
- "Controlling for baseline characteristics..."
- "Quality-adjusted life years (QALYs)"
- "Willingness-to-pay threshold"

**Avoid:**
- Marketing superlatives ("revolutionary", "unprecedented", "game-changing")
- Unqualified certainty ("This will definitely work")
- Excessive hedging ("might possibly perhaps potentially")

---

## IV. CITATIONS AND REFERENCES

### A. In-Text Citations: Chicago Manual Author-Date (AER Standard)

**Rules:**
- 1-3 authors: List all names
- 4+ authors: First author et al.
- Multiple citations: Chronological order, separated by semicolons

**Examples:**
```
The natural history demonstrates progressive renal decline (Ando et al. 2024;
Zaniew et al. 2018), with median ESKD onset at age 32 (Ando et al. 2024).

Cooper et al. (2020) report health state utility values for CKD populations.

Cost-effectiveness thresholds for ultra-rare diseases range from 100,000 to
380,000 dollars per QALY (Neumann et al. 2014; NICE 2017).
```

### B. Reference List Format

**Journal Articles:**
```
Ando, Taro, Koichi Miura, Tomoko Yabuuchi, Daisuke Ichikawa, Takeshi Yamamoto,
   and Akira Ashida. 2024. "Long-term Kidney Function of Lowe Syndrome: A
   Nationwide Study of Paediatric and Adult Patients." Nephrology Dialysis
   Transplantation 39 (8): 1360â€“63.
```

**Reports and Guidelines:**
```
NICE (National Institute for Health and Care Excellence). 2022. "NICE Health
   Technology Evaluations: The Manual." Process and methods PMG36. London: NICE.

United States Renal Data System. 2024. "USRDS Annual Data Report: Epidemiology
   of Kidney Disease in the United States." National Institutes of Health,
   National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
```

**Author Count:**
- 1-10 authors: List all names
- 11+ authors: First seven, then "et al."

### C. HTA-Specific Citations

**Agency Reports:**
```
CADTH (Canadian Agency for Drugs and Technologies in Health). 2024.
   "Etranacogene Dezaparvovec (Hemgenix) for Hemophilia B: Reimbursement
   Review." SG0805. Ottawa: CADTH.
```

**Clinical Guidelines:**
```
KDIGO (Kidney Disease: Improving Global Outcomes). 2012. "KDIGO Clinical
   Practice Guideline for the Evaluation and Management of Chronic Kidney
   Disease." Kidney International Supplements 3 (1): 1â€“150.
```

---

## V. MATHEMATICAL CONTENT

### A. Equations (AER Standard, Essential for Methodology)

**Format:**
- Display equations on separate lines
- Number consecutively at left margin: (1), (2), (3)
- Define all variables immediately after equation
- Use italics for scalars, boldface for vectors/matrices

**Example:**
```
The annual eGFR decline follows:

(1)    eGFR_{t+1} = eGFR_t - Î´ Ã— (1 - Î¸)

where Î´ is the natural decline rate (ml/min/1.73mÂ²/year) and Î¸ âˆˆ [0, 1] is
the treatment effect parameter.

The transition probability to ESKD is:

(2)    P(ESKD_t) = 1   if eGFR_t < 15
                 = 0   otherwise
```

**In-text fractions:** Use slash with clear parentheses
- Example: "The ratio (a + b)/(c + d) represents..."

### B. Notation Conventions

**Scalars:** *Italic* (e.g., *eGFR*, *t*, *c*, *Î´*, *Î¸*)
**Vectors:** **Boldface** (e.g., **x**, **Î²**)
**Matrices:** **Boldface** (e.g., **X**, **Î£**)
**Sets:** Script (e.g., ð’®, ð’³) or â„, â„¤, â„• for real/integers/natural numbers

**Subscripts and Superscripts:**
- Maximum two levels
- Example: *x*_{*i*,*t*} acceptable; *x*_{*i*,*t*,*j*}^{*k*,*l*} too complex

### C. When to Use Equations vs. Prose

**Use Equations For:**
- Core model structure (transition probabilities, Markov processes)
- Key calculations (ICER formula, discounting)
- Parameter relationships requiring mathematical precision

**Use Prose For:**
- Descriptive clinical parameters (prevalence, natural history)
- Implementation details (eligibility criteria, monitoring protocols)
- Budget impact calculations (can be prose with supporting tables)

---

## VI. TABLES

### A. Formatting Rules (AER Standard)

**Structure:**
- Portrait orientation only
- Maximum 9 columns (including row headings)
- **Horizontal lines ONLY** (no vertical lines)
- NO shading or cell fills
- NO asterisks for significance levels

**Caption Placement:** ABOVE table (opposite of figures)

**Numbering:** Consecutive Arabic numerals (Table 1, Table 2, etc.)

### B. Content Formatting

**Numbers:**
- Zero before decimal: 0.357 NOT .357
- Comma separators for large numbers: 1,229,454 NOT 1229454
- Consistent decimal places within columns

**Standard Errors:**
- Report in parentheses below estimates (NO asterisks)
- State calculation method in notes

**Panels:**
- Use "Panel A," "Panel B," etc. for grouped content within single table

### C. Table Notes and Footnotes

**Order:**
1. General notes
2. Table-specific footnotes (lowercase letters: a, b, c)
3. Source note

**Example:**
```
Table 1â€”Base Case Cost-Effectiveness Results

Scenario                    Incremental      Incremental      ICER
                           cost ($)          QALYs         ($/QALY)

Complete stabilization     2,258,437         6.879          328,288
                          (245,120)         (0.892)        (42,155)

70 percent reduction       2,515,603         3.939          638,682
                          (268,340)         (0.512)        (78,234)

Notes: Standard errors in parentheses, calculated using delta method with
1,000 bootstrap replications. ICER = incremental cost-effectiveness ratio.
All costs in 2024 USD, discounted at 3.5 percent annually. QALY = quality-
adjusted life year.
^a Treatment effect parameter Î¸ = 1.0 (complete stabilization).
Source: Authors' calculations based on Ando et al. (2024) and Wyld et al. (2012).
```

### D. HTA-Specific Table Content

**Include Tables For:**
- Base case cost-effectiveness results (essential)
- One-way sensitivity analysis results
- Scenario analysis comparisons
- Cost decomposition
- Budget impact by year
- Clinical trial summary (if multiple studies)
- Eligibility criteria (can be table or prose with bullets)
- Parameter inputs (often in appendix)

**Table Titles Should Be Descriptive:**
- Good: "Table 3â€”One-Way Deterministic Sensitivity Analysis (Scenario 1)"
- Avoid: "Table 3â€”Sensitivity Analysis"

---

## VII. FIGURES

### A. Technical Requirements (AER Standard)

**Format:** Vector-based graphics only
- Acceptable: PDF, EPS, AI, SVG
- NOT acceptable: JPG, PNG, BMP (raster formats)

**Variables in Figures:**
- Use *italics* for variables
- Use **boldface** for vectors/matrices
- Maintain consistency with equation notation

**Caption Placement:** BELOW figures (opposite of tables)

### B. Figure Types for HTA Reports

**Essential Figures:**
1. **Cost-Effectiveness Plane:** Incremental costs vs. incremental QALYs
   - Include willingness-to-pay threshold lines
   - Label scenarios clearly

2. **Disease Progression Diagram:** Health state transitions (Markov model)
   - Visual representation of model structure
   - Arrows showing allowed transitions

3. **Tornado Diagram:** One-way sensitivity analysis results
   - Horizontal bars showing parameter impact on ICER
   - Sorted by magnitude of influence

**Optional Figures:**
- Time-to-event curves (natural history)
- Probabilistic sensitivity analysis scatterplots
- Budget impact over time

### C. Figure Captions

**Format:**
```
[Figure displays here]

Figure 1. Cost-Effectiveness Plane: Gene Therapy Scenarios vs Natural History

Notes: Each point represents one treatment scenario. Dashed line indicates
$300,000/QALY threshold (NICE HST). Solid line indicates $150,000/QALY
conventional threshold. QALY = quality-adjusted life year.
Source: Authors' calculations.
```

---

## VIII. SECTION-SPECIFIC GUIDANCE

### A. Section I: Disease Background (HTA-Heavy, Descriptive)

**Style:** More comprehensive than typical AER introduction
- Use subsection headings liberally (A., B., C., 1., 2., 3.)
- Bullet points acceptable for clinical features
- Define all medical terminology
- Include prevalence, natural history, current treatments
- Explain molecular pathophysiology (shows understanding of gene therapy rationale)

**Length:** 15-20 pages acceptable (AER would be 3-5 pages)

**Tone:** Accessible to multidisciplinary audience (clinicians, economists, payers)

**Example Opening:**
```
I. Disease Background and Unmet Medical Need

Lowe syndrome, also known as oculocerebrorenal syndrome of Lowe (OCRL), is a
rare, X-linked recessive multisystem disorder first described in 1952. The
condition is characterized by the classic triad of congenital ocular
abnormalities, neurological impairment with intellectual disability, and
progressive renal tubular dysfunction (Attree et al. 2006).

A. Lowe Syndrome Overview

1. Disease Definition and Nomenclature

Lowe syndrome results from pathogenic mutations in the *OCRL* gene...
```

### B. Section II: Epidemiology (Hybrid AER-HTA)

**Style:** Analytical (AER) with comprehensive detail (HTA)
- Present prevalence estimation methodology rigorously
- If using novel estimation method (e.g., Zero-Inflated Poisson), show equations
- Provide country-specific estimates for key markets
- Discuss target population for treatment (eligibility criteria)

**Length:** 8-12 pages

**Include:**
- Methodology for prevalence estimation
- Global and country-specific prevalence
- Age distribution of prevalent cases
- Treatment-eligible population
- Incident cases annually

### C. Section III: Methodology (AER-Heavy, Rigorous)

**Style:** Pure AER analytical rigor
- Lead with model structure description
- Display equations for key relationships
- Define all parameters with literature citations
- Clearly state assumptions and limitations
- Use subsections: A. Model Structure, B. Clinical Parameters, C. Cost Parameters, D. Utility Parameters, E. Model Implementation

**Length:** 12-18 pages

**Equations Required:**
- eGFR decline formula
- Transition probability equations
- Mortality hazard equations
- ICER formula
- Discounting formula (if not standard)

**Parameter Tables:**
- Can be in main text (if concise) or appendix (if extensive)
- Must cite source for every parameter value

### D. Section IV: Results (AER Format)

**Style:** Pure AER presentation
- Lead with base case results (Table)
- Present sensitivity analysis systematically
- Use clear table formatting (horizontal lines only, standard errors in parentheses)
- Refer to figures by number in text
- Interpret results analytically without advocacy

**Length:** 10-15 pages

**Structure:**
```
IV. Results

A. Base Case Cost-Effectiveness

Table 1 presents lifetime costs, QALYs, and incremental cost-effectiveness
ratios for each treatment scenario relative to natural history. Under natural
history, patients starting at age 5...

[Table 1]

B. Sensitivity Analysis

1. One-Way Deterministic Sensitivity

Table 2 presents one-way sensitivity analysis results...

2. Threshold Analysis

We solve for the maximum gene therapy price that achieves specified ICER
thresholds...

C. Scenario Analysis

We examine alternative scenarios...
```

### E. Section V: Broader Value (HTA Extension)

**Style:** HTA-focused, qualitative
- Discuss value elements beyond QALY framework
- Use bullet points for multiple value dimensions
- Cite value frameworks (e.g., ISPOR, ICER Value Framework)
- Less technical than methodology section

**Length:** 5-8 pages

**Include:**
- Family/caregiver burden reduction
- Insurance value (financial risk protection)
- Severity of disease modifier
- Scientific spillover value
- Fear of contagion (if applicable, not for Lowe syndrome)
- Real option value (value of waiting for information)

### F. Section VI: Strategic Landscape (HTA-Heavy)

**Style:** HTA practical implementation focus
- Describe regulatory pathways
- Discuss market access considerations
- Explain reimbursement strategies (outcomes-based contracts, installment payments)
- Address manufacturing and delivery constraints

**Length:** 6-10 pages

**Include:**
- Regulatory status and pathways
- Competitive landscape
- Pricing and market access strategies
- Implementation considerations
- Stakeholder perspectives

### G. Section VII: Evidence Development Plan (HTA-Specific)

**Style:** Forward-looking, practical HTA guidance
- Outline key uncertainties identified in analysis
- Propose research studies to address gaps
- Discuss registry requirements
- Suggest real-world evidence collection strategies

**Length:** 4-6 pages

### H. Section VIII: Discussion and Conclusions (Hybrid)

**Style:** Balanced AER analytical summary with HTA implications
- Summarize key findings (AER)
- Acknowledge limitations explicitly
- Discuss policy implications (HTA)
- Provide clear recommendations with caveats

**Length:** 4-6 pages

**Structure:**
```
VIII. Discussion and Conclusions

A. Summary of Findings

Our analysis demonstrates that AAV-based gene therapy for Lowe syndrome yields
incremental cost-effectiveness ratios ranging from 328,288 to 1,446,388 dollars
per QALY, depending on treatment efficacy assumptions...

B. Limitations

This analysis has several limitations. First, absent clinical trial data...

C. Policy Implications

These findings suggest that gene therapy may achieve cost-effectiveness under
ultra-rare disease frameworks if efficacy approaches complete eGFR stabilization...

D. Conclusions

[Final summary paragraph]
```

---

## IX. STYLE COMPARISON EXAMPLES

### A. Disease Background Description

**Pure AER Style (Too Concise for HTA):**
```
Lowe syndrome is an X-linked disorder causing renal failure, with median ESKD
onset at age 32 (Ando et al. 2024). No disease-modifying treatments exist.
```

**Pure HTA Style (Too Descriptive for Economics):**
```
Lowe syndrome, also called oculocerebrorenal syndrome of Lowe, is a very rare
genetic condition that affects multiple parts of the body. Patients experience
problems with their eyes (cataracts), brain (intellectual disability), and
kidneys (kidney failure). It is caused by changes in a gene called OCRL on the
X chromosome. Families face tremendous challenges caring for affected children.
```

**Our Hybrid Style (Balanced):**
```
Lowe syndrome is a rare, X-linked recessive disorder characterized by the
classic triad of congenital cataracts, intellectual disability, and progressive
renal failure (Attree et al. 2006). The condition results from pathogenic
mutations in the *OCRL* gene, leading to deficiency of a phosphatidylinositol
phosphatase enzyme. Progressive kidney disease is the primary driver of
mortality, with median ESKD onset at age 32 (Ando et al. 2024). Currently, no
disease-modifying treatments exist; all management is symptomatic.
```

### B. Cost-Effectiveness Results

**Pure AER Style:**
```
III. Results

A. Base Case

Table 1 presents results. Complete stabilization yields an ICER of 328,288
dollars per QALY (SE 42,155).
```

**Pure HTA Style:**
```
Results

What We Found

The complete stabilization scenario (where the gene therapy completely stops
kidney disease from getting worse) costs an extra $2,258,437 but provides an
additional 6.879 quality-adjusted life years. This means the cost per QALY
gained is $328,288.

This is higher than the usual threshold of $150,000 per QALY that is often
used, but it is within the range that might be acceptable for very rare diseases
like Lowe syndrome.
```

**Our Hybrid Style:**
```
IV. Results

A. Base Case Cost-Effectiveness

Table 1 presents lifetime costs, QALYs, and incremental cost-effectiveness
ratios for each treatment scenario relative to natural history. Under natural
history, patients starting at age 5 with eGFR 70 ml/min/1.73mÂ² reach ESKD by
year 5, accumulate 5.87 discounted QALYs over 17.05 life years, and incur total
discounted costs of 1,229,454 dollars.

When gene therapy completely prevents eGFR decline (Î¸ = 1.0), patients maintain
CKD Stage 2 kidney function throughout their lifetime, never progressing to
ESKD. Life expectancy extends to 36.84 years, and patients accumulate 12.75
discounted QALYs. Total lifetime costs rise to 3,487,890 dollars, driven by the
3,000,000 dollar gene therapy acquisition cost and prolonged CKD Stage 2
management costs.

The incremental cost-effectiveness ratio is 328,288 dollars per QALY gained
(standard error 42,155 dollars). While exceeding conventional cost-effectiveness
thresholds of 100,000 to 150,000 dollars per QALY commonly referenced in United
States health technology assessment (Neumann et al. 2014), the ICER falls within
ranges considered for ultra-rare diseases under NICE's Highly Specialised
Technologies framework (up to 300,000 pounds per QALY, approximately 380,000
dollars) (NICE 2017).
```

---

## X. QUALITY CHECKLIST

### Before Submitting Any Section:

**AER Standards:**
- [ ] Equations numbered consecutively at left margin
- [ ] All scalars in *italics*, vectors in **boldface**
- [ ] Tables use horizontal lines only (no vertical lines, no shading)
- [ ] Standard errors in parentheses (NO asterisks for significance)
- [ ] Zero before decimals (0.357 not .357)
- [ ] Citations in author-date format (Smith 2020; Jones et al. 2019)
- [ ] Maximum 9 columns per table
- [ ] Figure captions BELOW figures, table captions ABOVE tables

**HTA Standards:**
- [ ] Clinical concepts defined on first use
- [ ] Prevalence and target population clearly stated
- [ ] Implementation considerations addressed
- [ ] Budget impact analysis included
- [ ] Limitations explicitly acknowledged
- [ ] Policy implications discussed
- [ ] Executive summary accessible to non-economists

**Hybrid Quality:**
- [ ] Tone is analytical but accessible
- [ ] Avoids marketing language and excessive jargon
- [ ] Balances conciseness with necessary detail
- [ ] Mathematical rigor in Methodology and Results
- [ ] Practical detail in Disease Background and Implementation sections
- [ ] Consistent notation throughout document
- [ ] All abbreviations defined on first use

---

## XI. SPECIFIC ADAPTATIONS FOR LOWE SYNDROME REPORT

### A. Tone Adjustments for Ultra-Rare Disease

**Acknowledge Uncertainty:** Ultra-rare diseases have limited data; be explicit
```
Good: "Absent clinical trial data for gene therapy in Lowe syndrome, we model
three treatment effect scenarios representing varying degrees of efficacy."

Avoid: "Gene therapy will achieve 70% reduction in eGFR decline."
```

**Emphasize Unmet Need:** Justified given severity and lack of alternatives
```
Appropriate: "Lowe syndrome represents a condition with profound unmet medical
need characterized by progressive, fatal disease course with no disease-modifying
treatments available."
```

**Discuss Broader Value:** More important for rare diseases than common conditions
```
Include discussion of: family burden, insurance value, severity modifier,
real option value of treating now vs. waiting for more data
```

### B. Handle Absence of Clinical Data

**Be Transparent:**
```
"We evaluate the cost-effectiveness of AAV-based gene therapy for Lowe syndrome
using a Markov cohort model. Absent clinical trial data, we model three
treatment effect scenarios representing plausible efficacy ranges based on
mechanistic understanding of OCRL enzyme restoration and precedent from related
gene therapies (Luxturna, Zolgensma)."
```

**Use Scenario Analysis Extensively:**
- Do not rely on single "base case" prediction
- Present multiple scenarios with clear efficacy assumptions
- Conduct threshold analysis (what efficacy level is needed for cost-effectiveness?)

### C. Emphasize Renal Focus

**Rationale for Kidney-Specific Modeling:**
```
"While Lowe syndrome affects multiple organ systems, we focus our economic
evaluation on renal outcomes for several reasons. First, progressive kidney
failure is the primary driver of mortality (Ando et al. 2024). Second, eGFR
decline provides a quantifiable, validated endpoint suitable for cost-
effectiveness modeling. Third, renal disease progression is potentially
modifiable through early intervention, unlike congenital ocular abnormalities
present at birth. Fourth, the economic impact of ESKD (dialysis costs exceeding
135,000 dollars annually) generates substantial potential offsets to gene therapy
acquisition costs."
```

---

## XII. REFERENCES FOR THIS STYLE GUIDE

### AER Guidelines:
- American Economic Association. "AER Style Guide." https://www.aeaweb.org/journals/aer/style-guide
- Chicago Manual of Style, 17th edition. Author-Date System.

### HTA Guidelines:
- NICE (National Institute for Health and Care Excellence). 2022. "NICE Health Technology Evaluations: The Manual." Process and methods PMG36.
- CADTH. 2017. "Guidelines for the Economic Evaluation of Health Technologies: Canada." 4th edition.
- ISPOR. "Pharmacoeconomic Guidelines Around the World." https://www.ispor.org/heor-resources/pharmacoeconomic-guidelines

### Gene Therapy HTA Precedents:
- NICE HST15: Onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy
- CADTH SG0805: Etranacogene dezaparvovec (Hemgenix) for hemophilia B
- NICE HST9: Voretigene neparvovec (Luxturna) for inherited retinal dystrophies

---

## XIII. DOCUMENT VERSION CONTROL

When revising sections, track major changes to ensure consistency:

**Version History Format:**
```
Version 1.0 (2025-11-11): Initial draft
Version 1.1 (2025-11-15): Revised Section III methodology based on updated parameters
Version 2.0 (2025-11-20): Major revision incorporating peer review comments
```

---

**END OF UNIFIED STYLE GUIDE**

This guide should be referenced throughout the writing and revision process to ensure consistency across all seven sections of the Lowe syndrome HTA report.
